Beximco Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Beximco Pharmaceuticals has a total shareholder equity of BDT53.6B and total debt of BDT4.9B, which brings its debt-to-equity ratio to 9.2%. Its total assets and total liabilities are BDT70.9B and BDT17.3B respectively. Beximco Pharmaceuticals's EBIT is BDT8.5B making its interest coverage ratio 7.9. It has cash and short-term investments of BDT1.3B.
Key information
9.2%
Debt to equity ratio
৳4.94b
Debt
| Interest coverage ratio | 7.9x |
| Cash | ৳1.31b |
| Equity | ৳53.60b |
| Total liabilities | ৳17.30b |
| Total assets | ৳70.90b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: R2WA's short term assets (BDT22.5B) exceed its short term liabilities (BDT9.3B).
Long Term Liabilities: R2WA's short term assets (BDT22.5B) exceed its long term liabilities (BDT8.0B).
Debt to Equity History and Analysis
Debt Level: R2WA's net debt to equity ratio (6.8%) is considered satisfactory.
Reducing Debt: R2WA's debt to equity ratio has reduced from 37.2% to 9.2% over the past 5 years.
Debt Coverage: R2WA's debt is well covered by operating cash flow (149%).
Interest Coverage: R2WA's interest payments on its debt are well covered by EBIT (7.9x coverage).